23. A pharmaceutical formulation comprising a therapeutically effective amount of a compound according to claim **1-21**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

24. The pharmaceutical formulation according to claim **22** or **23**, said formulation in a unit dosage format.

25. A compound according to claim **1-21**, or a pharmaceutically acceptable salt thereof, for use in the treatment of pain responsive to selective inhibition of the T Channel known as the $Ca_{v3.2}$ channel.

26. A compound according to claim **1-21**, or a pharmaceutically acceptable salt thereof, which is a selective T-type channel inhibitory compound useful for relief of neuropathic and/or inflammatory pain, and epilepsy.

27. A compound according to claim **1-21**, or a pharmaceutically acceptable salt thereof, for use in the treatment of pain, epilepsy, or essential tremor.

28. Use of a compound according to claim **1-21**, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pain responsive to selective inhibition of the T Channel known as the $Ca_{v3.2}$ channel, pain, epilepsy, or essential tremor.